Skip to main content

Advertisement

Table 3 Univariate and multivariate logistic regression analysis of factors contributing to NAE

From: High-dose thiotepa-related neurotoxicity and the role of tramadol in children

  n NAE (%) univariate Pa univariate OR (95% CI) multivariate Pb multivariate OR (95% CI)
Gender
 Boys 145 24 (17%)     
 Girls 106 22 (21%) 0.41 1.3 (0.7–2.5)   
Age
 No NAE 205 9.3 (6.3)f     
 Yes NAE 46 8.6 (5.2)f 0.48c    
Race
 Caucasian 186 31 (17%)     
 African 40 9 (23%) 0.51e    
 Others 25 6 (24%)     
Brain tumour
 No 135 18 (13%)   1   1
 Yes 116 28 (24%) 0.03 2.1 (1.1–4.0) 0.04 2.2 (1.0–4.6)
Neurological disorder at baseline
 No 230 38 (17%)   1   1
 Yes 20 8 (40%) 0.02 3.4 (1.3–8.8) 0.08 2.7 (0.9–8.4)
History of seizure
 No 238 42 (18%)   1   
 Yes 13 4 (31%) 0.27 2.1 (0.6–7.1)   
Thiotepa regimen
 600 mg/m2 129 18 (14%)     
 720 mg/m2 76 17 (22%) 0.18e    
 900 mg/m2 46 11 (24%)     
Alizaprided
 No 126 19 (15%)   1   1
 Yes 94 25 (27%) 0.04 2.0 (1.0–4.0) 0.13 1.7 (0.8–3.6)
Aprepitantd
 No 213 41 (19%)   1   
 Yes 7 3 (43%) 0.14 3.1 (0.7–14.6)   
Antipsychoticd
 No 180 34 (19%)   1   
 Yes 40 10 (25%) 0.39 1.4 (0.6–3.2)   
Proton Pump Inhibitord
 No 213 43 (20%)   1   
 Yes 7 1 (14%) 1 0.7 (0.1–5.6)   
Histamine H2-receptor antagonistd
 No 215 42 (20%)   1   
 Yes 5 2 (40%) 0.26 2.7 (0.4–17)   
Simple analgesicsd       
i.e. acetaminophen, nefopam       
 No 144 20 (13%)   1   
 Yes 76 14 (18%) 0.40 1.4 (0.7–3.0)   
Weak opioidsd       
i.e. tramadol, codeine, dextropropoxyphen       
 No 167 20 (12%)   1   1
 Yes 53 24 (45%) 0.0001 6.1 (3.0–12.4) 0.0001 6.3 (3.0–13.4)
Strong opioidsd       
i.e. morphine, pethidine       
 No 211 44 (21%)   1   
 Yes 9 4 (44%) 0.09 3.0 (0.8–11.8)   
  1. aFisher exact
  2. bTaking into account 4 factors: brain tumour (yes/no); neurological disorder at baseline (yes/no); alizapride intake (yes/no); weak opioids (yes/no)
  3. cStudent t test
  4. dData missing for 31 patients
  5. eChi-square test (2 df)
  6. fMean (SD)